Business
CLINUVEL preparing upgrade of ADR program to Level II, Nasdaq uplist
Executive summary plan to upgrade American Depository Receipt (ADR) program (CLVLY) to a Level II ADR listed on Nasdaq, expected before the end of 2025CLINUVEL’s primary listing on the ASX will remain unchanged as a result of the ADR uplistpreparation of Form 20-F for submission to U.S. SECNasdaq listing to enhance U.S. visibility, trading access and investor engagementapproximately 28% of CLINUVEL’s issued shares held by U.S.-based investorsno capital raising is proposed in connection with the
About this update from Clinuvel Pharmaceuticals Limited
[{"type":"image","alt":"Clinuvel Pharmaceuticals Limited","displaySize":"","headline":null,"caption":"Clinuvel Pharmaceuticals Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/6397a3f79f4dc9eb1683148adb10fab8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IZGfbstHkppwPJkoYvH5dQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6397a3f79f4dc9eb1683148adb10fab8","width":300,"height":157}},"lazy":false},{"type":"text","content":"Executive summary","length":17,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"plan to upgrade American Depository Receipt (ADR) program (CLVLY) to a Level II ADR listed on Nasdaq, expected before the end of 2025","length":133,"tagName":"p"}]},{"val":[{"type":"text","content":"CLINUVEL’s primary listing on the ASX will remain unchanged as a result of the ADR uplist","length":89,"tagName":"p"}]},{"val":[{"type":"text","content":"preparation of Form 20-F for submission to U.S. SEC","length":51,"tagName":"p"}]},{"val":[{"type":"text","content":"Nasdaq listing to enhance U.S. visibility, trading access and investor engagement","length":81,"tagName":"p"}]},{"val":[{"type":"text","content":"approximately 28% of CLINUVEL’s issued shares held by U.S.-based investors","length":74,"tagName":"p"}]},{"val":[{"type":"text","content":"no capital raising is proposed in connection with the ADR uplist","length":64,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":492,"olType":false},{"type":"text","content":"MELBOURNE, Australia, Aug. 22, 2025 (GLOBE NEWSWIRE) -- CLINUVEL is undertaking preparatory steps to upgrade its Level I American Depository Receipts (CLVLY), currently trading over-the-counter in the United States, to a Level II program listed on the Nasdaq Stock Market (Nasdaq). CLINUVEL’s primary listing on the Australian Securities Exchange (ASX) will remain unchanged.","length":381,"tagName":"p"},{"type":"text","content":"Work has commenced to file a Form 20-F registration statement with the U.S. Securities and Exchange Commission (SEC). CLINUVEL is currently undertaking legal, financial, and regulatory workstreams in support of this process, and has appointed U.S. legal counsel and an investment bank.","length":285,"tagName":"p"},{"type":"text","co...